Cyclic Peptide-Gadolinium Nanoparticles for Enhanced Intracellular Delivery.
Amir Nasrolahi ShiraziShang Eun ParkShirin RadLuiza BaloyanDindyal MandalMuhammad Imran SajidRyley HallSandeep LohanKhalid ZoghebiKeykavous ParangRakesh Kumar TiwariPublished in: Pharmaceutics (2020)
A cyclic peptide containing one cysteine and five alternating tryptophan and arginine amino acids [(WR)5C] was synthesized using Fmoc/tBu solid-phase methodology. The ability of the synthesized cyclic peptide to produce gadolinium nanoparticles through an in situ one-pot mixing of an aqueous solution of GdCl3 with [(WR)5C] peptide solution was evaluated. Transmission electron microscopy showed the formed peptide-Gd nanoparticles in star-shape morphology with a size of ~250 nm. Flow cytometry investigation showed that the cellular uptake of a cell-impermeable fluorescence-labeled phosphopeptide (F'-GpYEEI, where F' = fluorescein) was approximately six times higher in the presence of [(WR)5C]-Gd nanoparticles than those of F'-GpYEEI alone in human leukemia adenocarcinoma (CCRF-CEM) cells after 2 h incubation. The antiproliferative activities of cisplatin and carboplatin (5 µM) were increased in the presence of [(WR)5C]-GdNPs (50 μM) by 41% and 18%, respectively, after 72-h incubation in CCRF-CEM cells. The intracellular release of epirubicin, an anticancer drug, from the complex showed that 15% and 60% of the drug was released intracellularly within 12 and 48 h, respectively. This report provides insight about using a non-toxic MRI agent, gadolinium nanoparticles, for the delivery of various types of molecular cargos.
Keyphrases
- induced apoptosis
- flow cytometry
- contrast enhanced
- aqueous solution
- magnetic resonance imaging
- cell cycle arrest
- amino acid
- squamous cell carcinoma
- endothelial cells
- computed tomography
- emergency department
- electron microscopy
- magnetic resonance
- acute myeloid leukemia
- walled carbon nanotubes
- stem cells
- oxidative stress
- signaling pathway
- photodynamic therapy
- cell therapy
- clinical trial
- single molecule
- radiation therapy
- mesenchymal stem cells
- pet imaging
- adverse drug
- electronic health record
- rectal cancer